Drug Trial Radar · NCT07049562
Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects
Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
May 21, 2025
Primary completion
Jun 18, 2025
Study completion Jun 18, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the absorption, metabolism and excretion after a single intravenous infusion of \[14C\]HRS-8427 in healthy Chinese subjects
Conditions
- Healthy Cninese Adult Male
Interventions
HRS-8427Drug
\[14C\] HRS-8427 for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The total radioactive recovery rate and cumulative total radioactive recovery rate at each time interval in excreta (urine and feces)Time frame: 0~120hours
- The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered doseTime frame: 0~120hours
- TmaxTime frame: 0~48hours
- CmaxTime frame: 0~48hours
- t1/2Time frame: 0~48hours
- MRTTime frame: 0~48hours
- AUCTime frame: 0~48hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.